Pancreatectomy Clinical Trial
— SHIELDSOfficial title:
Prospective, Multicenter Study to Evaluate the Safety and Performance of a syntHetic Tissue Sealant in Reducing fluId lEakage Following Elective hepatobiLiary anD Pancreatic Surgery
NCT number | NCT04024956 |
Other study ID # | CIP-3 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 25, 2020 |
Est. completion date | May 26, 2023 |
Verified date | June 2023 |
Source | Polyganics BV |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans. This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas. The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy. The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.
Status | Completed |
Enrollment | 80 |
Est. completion date | May 26, 2023 |
Est. primary completion date | November 19, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Preoperative inclusion criteria: Subjects will be eligible according the following criteria: 1. Subjects who are able to provide a written informed consent prior to participating in the clinical investigation. 2. Subjects who are = 18 years old. 3. Subjects who are able to comply with the follow-up or other requirements. 4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy. During the surgery, the patients also need to comply with the intraoperative criteria. Intraoperative inclusion criteria: Subjects will be eligible according the following criteria: 1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure). Exclusion Criteria: Preoperative exclusion criteria Subjects who meet any of the following criteria will be excluded from participation: 1. Female subjects who are pregnant and/or breastfeeding. 2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)). 3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid). 4. Subjects who receive double-coagulation. 5. Subjects who receive peritoneal dialysis. 6. Subjects who previously required liver transplantation. 7. Subjects with a presence of systemic infection. 8. Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening. 9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple). Intraoperative exclusion criteria: Subjects who meet any of the following criteria will be excluded from participation: 1. Subjects with multivisceral resections, except resection of spleen. 2. Not able to apply the patch(es) according to the Instructions For Use. 3. Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2). Additional for liver group: 4. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016). 5. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score. Additional for pancreas group: 6. Subjects with a margin of < 1 cm between the defect and the portal vein. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitats Klinikum Hamburg-Eppendorf | Hamburg | |
Germany | University Hospital Oldenburg | Oldenburg |
Lead Sponsor | Collaborator |
---|---|
Polyganics BV | Genae |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bile leakage | Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C | 30 days | |
Primary | Pancreatic leakage | Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C | 30 days | |
Secondary | Bleeding | Intra-operative control bleeding | Day 1 | |
Secondary | Leak-associated comorbidities | Incidence of leak-associated comorbidities | 16 months | |
Secondary | re-intervention | Incidence of re-intervention | 16 months | |
Secondary | Ease of Use | Ease of Use of the device as measured by questionnaire | Day 1 | |
Secondary | Post-operative bile leakage | Incidence of post-operative bile leakage (liver only) | 90 and 180 days | |
Secondary | Post-hepatectomy haemorrhage (PHH) | Incidence of post-operative bleeding (liver only) | 30 days | |
Secondary | Post-operative pancreatic juice leakage | Incidence of post-operative pancreatic juice leakage (pancreas only) | 90 and 180 days | |
Secondary | Post-pancreatectomy haemorrhage (PPH) | Incidence of post-operative bleeding (pancreas only) | 30 days | |
Secondary | (Serious) Adverse Device Effects | Incidence of (Serious) Adverse Device Effects | 16 months | |
Secondary | Incidence of transfusion | Incidence of transfusion | 16 months | |
Secondary | Length of hospital stay | Length of hospital stay | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06208579 -
Feasibility and Effectiveness of Augmented Reality Assistance System for Pancreatic Surgery
|
||
Completed |
NCT00414908 -
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
|
Phase 3 | |
Completed |
NCT00559364 -
Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea
|
Phase 3 | |
Active, not recruiting |
NCT04431076 -
Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes
|
||
Recruiting |
NCT05297136 -
Preoperative Endoscopic Pancreatic Stent for Distal Pancreatectomy
|
N/A | |
Completed |
NCT03060408 -
Comparison of Fluid Requirements in Pancreatectomy: Laparotomy vs. Laparoscopy
|
N/A | |
Recruiting |
NCT02230436 -
Early Versus Late Drain Removal After Pancreatectomy: A Randomized Prospective Trial
|
N/A | |
Completed |
NCT02509910 -
Implementation of a GDT Algorithm for Major Surgery Patients
|
N/A | |
Completed |
NCT01929902 -
Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery
|
||
Terminated |
NCT02617979 -
Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement
|
N/A | |
Recruiting |
NCT06126601 -
Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety
|
||
Terminated |
NCT02649023 -
Deep Venous Thrombosis After Hepatobiliopancreatic Surgery
|
||
Completed |
NCT02623803 -
Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies
|
Phase 4 | |
Completed |
NCT02814812 -
Postoperative Comput Tomography as a Predictor of Postoperative Complications After Pancreatic Surgery
|
N/A | |
Completed |
NCT06424431 -
Methods of Pancreatic Stump Closure for Distal Pancreatectomy
|
N/A | |
Active, not recruiting |
NCT04423731 -
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
|
||
Recruiting |
NCT05856474 -
Management of Traumatic Pancreas Transection
|
||
Not yet recruiting |
NCT05992857 -
Pancreaticoduodenectomies With Complete Arterial Coverage by Retromesenteric Omentoplasty
|
N/A | |
Completed |
NCT01950845 -
Automated Versus Manual Fluid Management for High Risk Abdominal Surgical Patient. A Prospective, Randomized Trial
|
N/A | |
Not yet recruiting |
NCT04850430 -
Gastric Venous Reconstruction After Total Pancreatectomy
|
N/A |